Cautiously optimistic for rest of 2010 and improving margins overall. Efficient, and ready to take advantage of improving economic activity.
Introduced new innovative products.
Acquisitions produce enhanced income of 14% with integration activities regarding Sierra still in progress so there is full integration to look forward to. Expected return to double-digit growth in several markets.
Awaiting FDA approval for clinical trials which can begin quie
Good integration with BRAVO with improved margins and with expected similar improvements with SIERRA.
Colon2 accelerated sales and penetrating new markets.